Kornimate/medical-research-clean huggingface dataset:
effect of oral vitamin d supplement on atopic dermatitis; a clinical trial with staphylococcus aureus colonization determination

Conditions: Atopic Dermatitis

Summary: background: increase in skin colonization of staphylococcus aureus (s. aureus) in atopic dermatitis patients (ad) resulted from the reduction of cathelicidin production in these patients plays the important role in pathogenesis of this disease. recently in vivo study has showed that vitamin d can stimulate cathelicidin production. oral supplement of vitamin d might be beneficial in atopic dermatitis. objective: to determine the effect of oral vitamin d supplement on clinical impact including skin colonization of s. aureus in atopic dermatitis patients.


Eligibility criteria:
inclusion criteria: * eligible criteria included patients with mild to moderate atopic dermatitis by scorad (scoring for atopic dermatitis) score criteria1,17,18, age between 1-18 years old. all patients had been advised to take normal, dietary product and their activities. they had been advised to discontinue at least 4 weeks of oral corticosteroid, at least 2 weeks of topical corticosteroid or topical calcineurin inhibitor application and at least 6 months of vitamin supplement prior to starting the protocol exclusion criteria: * the exclusion criteria were to coexisting skin infection on top with ad lesions, known case of primary or secondary immune-compromised host, hepatic or renal disease, those taking vitamin d or nutraceutical supplementation, those continues taking with antibiotics, corticosteroid, immunosuppressive agents, anti-epileptic drugs, thiazide diuretics, proton-pump inhibitors, histamine 2-receptor antagonists at the time of enrollment. patients who used topical antiseptic or antibiotic products during study period were also excluded. patients who developed worsening of ad with flare-up of clinical manifestation or scorad greater than 40, secondary infection on-top tested lesions were excluded from data analysis.

Keywords: atopic dermatitis, vitamin d supplementation, cathelicidin, staphylococcus aureus colonization, scorad score
paclitaxel and carboplatin combination as 1st line treatment in ovarian carcinomas

Conditions: Ovarian Cancer

Summary: this trial will determine the feasibility and toxicity of dose intense (every 2 weeks) of paclitaxel+carboplatin combination following cytoreductive surgery in patients with stage ic-iv ovarian cancer.

dose dense chemotherapy has been proven beneficial in various oncological settings. it is proposed that this concept be tested in ovarian cancer, with the support of growth factors. it is hypothesized that, if feasible, dose-dense chemotherapy may be more effective.

Eligibility criteria:
inclusion criteria: * histologically- or cytologically- confirmed ovarian cancer requiring standard chemotherapy * patients have to be chemotherapy naive * patients may have undergone cytoreductive surgery, or this may have been omitted due to dissemination * age \>18 years. * performance status (who) 0-2 * life expectancy of at least three months. * adequate bone marrow function (absolute neutrophil count \>1000/mm\^3, platelet count\>100000/mm\^3, hemoglobin\>9gr/mm\^3). * adequate liver (bilirubin\<1.5 times upper limit of normal and sgot/sgpt\<2 times upper limit of normal) and renal function (creatinine\<2mg/dl) * informed consent exclusion criteria: * pregnant or nursing * psychiatric illness or social situation that would preclude study compliance' * other concurrent uncontrolled illness * no other invasive malignancy within the past 5 years except nonmelanoma skin cancer

Keywords: cancer ovarian cancer dose-dense chemotherapy
virtual reality decreases child anxiety and pain as well as caregiver anxiety and pain perception during orthopaedic clinic office procedures

Conditions: Anxiety; Pain

Summary: the purpose of this study is to demonstrate that the use of a virtual reality experience can decrease child and caregiver anxiety and pain for simple orthopaedic office procedures.


Eligibility criteria:
inclusion criteria for pediatric patient: * undergoing cast removal, pin removal, or suture removal in study affiliated clinic * less than 17 years old exclusion criteria for pediatric patient: * history of seizures * pregnant, have preexisting binocular vision abnormalities or psychiatric disorders, or suffer from a heart condition or other serious medical condition * patients can't have implanted medical devices including cardiac pacemakers, hearing aids and defibrillators there is no minimum or maximum age for the caretakers/parents.

Keywords: virtual reality
a retrospective observational study of ustekinumab among bio-naive participants with crohn's disease in china

Conditions: Crohn Disease

Summary: bio-naive participants are defined as the participants who previously have not received any biologics for crohn's disease (cd).the purpose of this retrospective study is to describe the endoscopic remission at week 24 among bio-naive participants with cd treated with ustekinumab in china.


Eligibility criteria:
inclusion criteria: * participants with diagnosis of active crohn's disease (cd) (that is, crohn's disease activity index \[cdai\] greater than or equal to \[\>=\] 150; harvey-bradshaw index \[hbi\] \>=5; or determined by physicians) * participants with initiation of ustekinumab intravenous induction therapy for the first time between 20 may 2020 and 16 september 2022 exclusion criteria: * previously received ustekinumab for any indication other than cd * participants were previously exposed with any biologics (for example: adalimumab, infliximab, vedolizumab or their biosimilars) other than ustekinumab
effects of myo-inositol in women with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome; Resistance, Insulin; Glucose Intolerance

Summary: the study will be carried out at the hospital of the medical school of sao paulo (hc-fmusp) and the goal is to compare the effects of the administration of myo-inositol in relation to the effects of metformin in women with polycystic ovary syndrome and insulin resistance or glucose intolerance. menstrual cycle, hyperandrogenism, chronic inflammatory process, carbohydrate metabolism, hepatic steatosis will be evaluated. in total, 60 women in the reproductive period, with a variable age between 18 and 36 years old will be recruited and randomized in two groups: intervention- myo-inositol for 6 months, control group will use metformin also for 6 months.

the study will involve 60 women in the reproductive period, with a variable between 19 and 36 years old and diagnosed with polycystic ovary syndrome (pcos), according to rotterdam- european society of human reproduction and embryology (eshre) / american society for reproductive medicine (asrm) criteria defined in 2003 and revised in 2018, and insulin resistance (presence acanthosis nigricans) or glucose intolerance (fasting glycemia, glycated hemoglobin or 75g glycemic overload and blood glucose assessment after 2 hours). it is a comparative and non-inferiority study of myo-inositol in relation to metformin. they will be divided into two groups of 30 patients: group i (control) - they will receive metformin 850 mg, orally, twice a day; group ii (experiment) - they will receive myo-inositol 2g + folic acid 200mcg, orally, twice a day.

Eligibility criteria:
inclusion criteria: * women aged 19 to 36 with diagnosis of pcos and insulin resistance or glucose intolerance. exclusion criteria: * previous use of any hormonal treatment in the past three months; * other causes of anovulation; * gynecological or other associated conditions (endometriosis, adenomyosis or diabetes mellitus); * fsh (follicle stimulating hormone) \> 15 ul / l (2nd to 5th day of the cycle); * beta-hcg (human chorionic gonadotropin) positive (pregnancy).

Keywords: myo-inositol metformin polycystic ovary syndrome resistance insulin glucose intolerance
antidepressant medication treatment for depression in individuals with chronic heart failure

Conditions: Heart Failure, Congestive; Chronic Heart Failure; Depression

Summary: this study will examine the effect of antidepressant medication on rates of death and disease in depressed people with chronic heart failure.

comorbid depression in people with chronic medical illness is a serious public health concern. depressive disorders lead to increased morbidity, mortality, and poorer outcomes in ischemic heart disease, a leading cause of chronic heart failure (chf). evidence suggests that a relationship exists between depression and chf; studies that examine the way chf is affected by depression treatments are needed. participants in this study will be randomly assigned to receive either sertraline or placebo for 12 weeks. assessments will be made at weeks 2, 4, 6, 8, 10, and 12. participants who do not respond to their treatment will have their medication dose adjusted following assessment. interviews and rating scales will be used to assess depressive symptoms, cognitive status, psychiatric comorbidity, daily and chronic stress, and social support. a follow-up visit will take place 6 months, 1 year, 2 years, and 3 years after study completion.

Eligibility criteria:
inclusion criteria: * chronic heart failure * diagnostic and statistical manual- fourth edition (dsm-iv) criteria for major depression * current use of any antipsychotic medication at study entry exclusion criteria: * life-threatening comorbidity with a 50% or higher likelihood of death within 1 year * history of psychoses, bipolar disorder, or severe personality disorder * history of alcohol or drug dependence in the last year * severe physical disability that may interfere with the study * neurological impairment * active suicidal ideations * current use of antidepressant medication(s) at the start of study medication

Keywords: antidepressive agents
clinical and histological evaluation of the 755nm alexandrite laser with handpiece for the treatment of scars

Conditions: Scars

Summary: compare efficacy and safety of handpieces on the 755nm alexandrite laser for the treatment of scars.


Eligibility criteria:
inclusion criteria: 1. is a healthy male or female between 18 and 85 years old 2. has unwanted scars not including atrophic scars and wishes to undergo laser treatments. 3. is willing to consent to participate in the study. 4. is willing to comply with all requirements of the study including biopsies, being photographed, following post treatment care and attending all treatment and follow up visits. 5. has fitzpatrick skin types i to iv. exclusion criteria: 1. the subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. 2. the subject is hypersensitive to light exposure or takes photo sensitized medication. 3. the subject has active or localized systemic infections. 4. the subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy {greater than 81 mg per day}). 5. the subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. 6. the subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study. 7. the subject has used accutane within 6 months prior to enrollment. 8. the subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. 9. the subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate). 10. the subject has a history of keloids. 11. the subject has evidence of compromised wound healing. 12. the subject has a history of squamous cell carcinoma or melanoma. 13. the subject has a history of immunosuppression/immune deficiency disorders (including hiv infection or aids) or use of immunosuppressive medications. 14. the subjects has an allergy to lidocaine and epinephrine.
nitric oxide mediated vasodilatory response to hawthorn standardized extract

Conditions: Prehypertension; Mild Hypertension

Summary: prehypertension and mild hypertension affect an estimated 157 million u.s. adults. cardiovascular disease (cvd) risk and associated mortality is elevated in this population. treatment options are limited consisting of lifestyle modification, which is often ineffective, or drug therapy, which carries risk of side effects. highly safe, efficacious, and acceptable treatment options for this population are needed. hawthorn standardized extract (hse) is approved for use in europe to treat heart failure, and preliminary evidence suggests it may have a blood pressure lowering effect. however, prior trials of hawthorn have based dosage recommendations on animal studies. therefore, the investigators propose a dose-finding study to measure the pharmacodynamic effect of three doses of standardized hawthorn extract and placebo.


Eligibility criteria:
inclusion criteria: 1. recent ambulatory daytime systolic bp average between 120 - 155 mmhg or diastolic bp between 80-95 mmhg 2. age 18 years and older. 3. ability to speak english exclusion criteria: 1. any antihypertensive medication use (ace inhibitors, arb, beta-blockers, calcium channel blockers, diuretics, alpha agonists or antagonists, nitrates, direct vasodilators such as hydralazine, aldosterone antagonists, direct renin inhibitors, endothelin antagonists) 2. current tobacco use. 3. diagnosed with diabetes, known coronary artery disease, severe aortic stenosis, idiopathic hypertrophic subaortic stenosis (ihss), or upper extremity vascular obstruction. 4. pregnancy or breast feeding. 5. using estrogen-containing birth control methods. 6. unwillingness to forgo vitamins c and e, fish oil, niacin, arginine, otc decongestants, and nsaids such as advil, motrin, and nuprin during the study period. 7. unwillingness to forgo use of phosphodiesterase inhibitors (sildenafil - 36 hours, vardenafil - 36 hours, tadalafil - 96 hours) prior to study visits. 8. unwillingness to refrain from vigorous exercise on the morning of study visits. 9. women with childbearing potential who do not agree to practice effective birth control (condom, diaphragm, cervical cap, copper iud, abstinence).

Keywords: prehypertension mild hypertension flow mediated dilation hawthorn
a nurse led patient management programme to improve outcomes in gout

Conditions: Gout; Arthritis; Crystal Arthropathy

Summary: this study evaluates the addition of a structured nurse led patient management programme to standard of care in gout patients. half of the patient will receive the nurse led programme in addition to standard of care and the other half will receive standard of care only.

there is evidence from other chronic diseases that nurse led care in addition to standard of care ameliorates outcomes. in gout the primary target is the serum uric acid level (sua). we intend to demonstrate the superiority of a structured nurse led patient management programme over standard of care in a randomized controlled study. the primary endpoint is the percentage of patients reaching the target sua level at 6 months follow-up.

Eligibility criteria:
inclusion criteria: * proven diagnosis of gout according to aspiration of monosodium urate (msu) crystals or positive dual energy computer tomography (dect) or american college of rheumatology (acr) criteria 2015 fulfilled (1) * written informed consent * age \>=18 years * ability and willingness to follow a fixed outpatient programme as judged by the investigator * indication for urate-lowering therapy (ult) * in case of established disease and intercritical gout a sua level over 360 umol per liter is mandatory. exclusion criteria: * informed consent not obtained * age \<18 years * inability or unwillingness to follow a fixed outpatient programme as judged by the investigator * no definite diagnosis of gout * no indication for ult or contraindications against ult * in case of established disease and intercritical gout a sua level \<360 umol per liter is an exclusion criterion * pregnant or breastfeeding women can´t participate.

Keywords: outcome gout
the effect of tracleer® on male fertility

Conditions: Hypertension, Pulmonary

Summary: the objective of the study is to evaluate the effects of chronic tracleer® treatment on testicular function via semen analysis in male patients with primary pulmonary arterial hypertension (pah).


Eligibility criteria:
inclusion criteria: * male patients age 18-65 years. * bosentan-naïve. * pph, who functional class iii/iv, in need of tracleer * patients pulmonary arterial hypertension (pah) secondary to congenital heart disease. * written informed consent. exclusion criteria: * female * patients with pah secondary to connective tissue vascular diseases or hiv. * patients who have undergone a vasectomy. * patients with an average baseline sperm concentration \< 15 x 10\[6\]/ml, or any sample with a sperm concentration \<= 7.5 x 10\[6\]/ml. * patients with an average baseline sperm motility \<20% or normal sperm morphology \<5%. * body weight \< 50 kg. * hypotension, defined as systolic blood pressure less than 85 mm hg. * ast and/or alt plasma levels greater than 3 times uln. * hypersensitivity to bosentan or any of the components of the formulation. * treatment with glyburide, cyclosporine a or tacrolimus at inclusion or planned during the study. * treatment with hormone suppressive agents, including androgens, estrogens, anabolic steroids or glucocorticoids within the past 6 months or planned during the study. * current treatment less than 3 months prior to inclusion or planned treatment with prostacyclin or prostacyclin analogues (e.g., flolanâ or remodulin). * patients who received an investigational drug in the month preceding the study start or who are due to be treated with another investigational drug during the study period. * known drug or alcohol dependence or any other factors that will interfere with conduct of the study. * any illness other than pph that will reduce life expectancy to less than 6 months. * active cancer. * prior treatment with an anti-neoplastic agent or ionizing radiation. * hot tub/jacuzzi use. * uncontrolled diseases including diabetes, liver or kidney disease. * patients receiving spironolactone (aldactone) less than 3 months prior to inclusion or dose \>25 mg/day at baseline or anytime during the study.
oral human papillomavirus infection in hiv-infected men

Conditions: Papillomavirus Infections; HIV Infections

Summary: human papillomavirus (hpv)-infection belong to the most common sexually transmitted diseases worldwide. hiv-infected men having sex with men /msm) are strongly associated with a higher prevalence of genitoanal hpv-infection, and perianal hpv-infections have been detected in up to 90% of hiv-positive men. the data concerning the incidence of oral hpv-infection in hiv-positive men, especially in the era of highly antiretroviral therapy, are conflicting. thus, this prospective study mainly focuses on the incidence and prevalence of oral hpv-infection, spectrum of hpv-types, and oral high-risk hpv viral load in hiv-positive men.

human papillomavirus (hpv)-infection belong to the most common sexually transmitted diseases worldwide. estimated prevalences of subclinical genital hpv-infection in the immunocompetent sexually active population range from 10 to above 50%. genetic or iatrogenic immunosuppression is known to play a decisive role in the initiation of a variety of cutaneous neoplasias and their precursor lesions. in this context, hpv-associated anogenital malignancies occur with high frequency in patients with hiv-infection. in several studies, perianal hpv-infections have been detected in up to 90% of hiv-positive men and a high incidence of anal dysplasia has been reported in these patients. the data concerning the incidence of oral hpv-infection in hiv-positive men, especially in the era of highly antiretroviral therapy, are conflicting. thus, this prospective study mainly focuses on the incidence and prevalence of oral hpv-infection, spectrum of hpv-types, and oral high-risk hpv viral load in hiv-positive men.

Eligibility criteria:
inclusion criteria: * hiv-infected men who have sex with men exclusion criteria: * none

Keywords: oral human papillomavirus infection hiv-infection high-risk hpv viral load oral human papillomavirus infection in hiv-positive men treatment experienced treatment naive
analysis of the early development of the visual function in extreme premature infants under 28th weeks of gestation

Conditions: Vision

Summary: the aim of this study is to collect data on the early visual development of extreme premature infants. the method is the measurement of flash visual evoked potentials and the study population includes premature infants under the 28th weeks of gestation, who have normal cranial ultrasound examinations, normal aeeg, no clinical neurological symptoms and who have a normal ophthalmological status. fvep measurements were recorded from the first week of life every second week until term. the fvep recordings were performed in active sleep, in stable premature infants, who were continuously monitored. the nihon kohden neuropack 8 was used, the stimulus frequency was 0,5 hz, artefact free averages were analyzed. the measurements were analyzed according to the presence and absence of known waveforms, their latencies and amplitudes. longitudinal analysis was performed to analyse the effect of extrauterine visual development on fvep with growing gestational ages.


Eligibility criteria:
inclusion criteria: * all premature infants under the 29th week of gestation entering our ward. exclusion criteria: * infants with intracranial abnormalities, cerebral malformations, neurological symptoms or known eye pathology.
telemedicine for narcolepsy

Conditions: Narcolepsy

Summary: the tenar trial is the first randomized controlled trial (rct) designed to evaluate the feasibility, efficacy, safety, and costs of a telemedicine multidisciplinary approach for the management of narcolepsy. open rct assessing the non-inferiority of the multidisciplinary management of narcolepsy via video consultation (vc) through mobile telemedicine devices compared to usual in-office care. 202 children and adults with narcolepsy will be randomly allocated in 1:1 ratio to vc or in-office usual care for a 12 months follow-up. at baseline, all patients will undergo a neurologic, metabolic, and psychosocial assessment. primary (i.e., excessive daytime sleepiness according to the epworth sleepiness scale) and secondary endpoints (i.e., other symptoms, metabolic control, quality of life, patient and family satisfaction with care, feasibility, safety, and costs) will be measured at 6 and 12 months. the investigators expect the telemedicine approach not only to be non-inferior for sleepiness control but also to significantly improve other patient-centred outcomes compared to the usual in-office care.


Eligibility criteria:
inclusion criteria: • adolescents (≥14 years old) and adults with a diagnosis of narcolepsy according to icsd-3 criteria at their first ("incident") or with established diagnosis ("prevalent" subjects), able to provide consent exclusion criteria: * inability to read, write, or using a tablet; * major psychiatric disorders.